US Stock Movement | Genmab (GMAB.US) surges nearly 26% intraday, reaching a record high

According to Zhiyan Finance APP, on Wednesday, Genmab (GMAB.US) opened higher and continued to rise. As of press time, it had gained nearly 26%, with an increase of over 58% in October. According to reports, Genmab announced the latest data from its phase III LiGeR-HN1 trial of Petosemtamab, showing that the combined therapy can reduce the risk of death in patients with squamous cell carcinoma of the head and neck by 50%. Genmab stated that a phase III clinical trial of petosemtamab in combination with pembrolizumab achieved two primary endpoints. The study evaluated this combination regimen as a first-line treatment in PD-L1 positive, recurrent or metastatic squamous cell carcinoma of the head and neck. The company added that, compared to pembrolizumab monotherapy, this combined regimen reduced the risk of death by 50%.